{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gilberts-syndrome/diagnosis/differential-diagnosis/","result":{"pageContext":{"chapter":{"id":"56e4f62e-6140-5b88-b779-3cf820e68d7e","slug":"differential-diagnosis","fullItemName":"Differential diagnosis","depth":2,"htmlHeader":"<!-- begin field 212dde37-6ff7-4660-b4be-b7eeffa420d7 --><h2>What else might it be?</h2><!-- end field 212dde37-6ff7-4660-b4be-b7eeffa420d7 -->","summary":"","htmlStringContent":"<!-- begin item 519a0e4e-3fd2-4e9a-9604-238cd10ad230 --><!-- begin field cd4001ae-db0c-4b38-990c-9ebdcfa80f3a --><ul><li><strong>Other causes of unconjugated hyperbilirubinaemia include:</strong><ul><li><strong>Haemolysis</strong><ul><li>Auto-immune haemolytic anaemias.</li><li><a class=\"topic-reference external-reference\" href=\"/topics/sickle-cell-disease/\">Sickle cell anaemia</a>.</li><li>Thalassaemia.</li><li>Hereditary spherocytosis.</li><li>Glucose-6-phosphate dehydrogenase deficiency.</li><li>Prosthetic heart valves.</li><li>Reabsorption of a large haematoma (excessive haemoglobin breakdown increases bilirubin production).</li></ul></li><li><strong>Genetic causes.</strong><ul><li>Crigler–Najjar syndrome type I  a rare, recessively inherited condition in which there is no bilirubin conjugation in the liver, resulting in severe progressive jaundice in neonates in the first few days of life. If left untreated, it leads to bilirubin encephalopathy (kernicterus). Bilirubin levels reach 350–950 micromol/L and life expectancy is usually less than 1 year.</li><li>Crigler–Najjar syndrome type II —  an inherited condition that is thought to be due to a combination of a Gilbert's syndrome defect and a Crigler–Najjar type I defect, in which conjugating enzyme activity is less than 10%. It is less severe than type I and brain damage does not occur. Bilirubin levels are less than 350 micromol/L.</li></ul></li><li><strong>Drugs</strong><ul><li>Methyldopa and sulfasalazine can cause haemolysis.</li><li>Rifampicin can impair hepatic bilirubin clearance.</li></ul></li><li><strong>Physiological neonatal jaundice.</strong><ul><li>Harmless unconjugated hyperbilirubinemia, often with mild clinical jaundice, occurs in all full term newborn infants. The bilirubin concentration increases to a maximum 2–5 days after birth and rarely exceeds 90 micromol/L. It is more severe in preterm babies owing to the combination of immaturity of enzymes and added bilirubin load from rapid haemolysis of surplus fetal red blood cells in the neonatal period. Breastfeeding slightly increases serum bilirubin levels.</li></ul></li></ul></li><li><strong>Causes of conjugated hyperbilirubinaemia include:</strong><ul><li><strong><a class=\"topic-reference external-reference\" href=\"/topics/gallstones/\">Gallstones</a>.</strong></li><li><strong><a class=\"topic-reference external-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/\">Fatty liver disease</a>.</strong></li><li><strong>Infection:</strong><ul><li>Viral hepatitis. (For further information see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/hepatitis-a/\">Hepatitis A</a>, <a class=\"topic-reference external-reference\" href=\"/topics/hepatitis-b/\">Hepatitis B</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/hepatitis-c/\">Hepatitis C</a>.</li><li>Cytomegalovirus.</li><li>Epstein-Barr virus.</li></ul></li><li><strong>Drugs:</strong><ul><li>Paracetamol <a class=\"topic-reference external-reference\" href=\"/topics/poisoning-or-overdose/\">poisoning</a> — a subset of people with Gilbert's syndrome may be more susceptible to liver damage after an overdose.</li><li>Alcoholic hepatitis.</li><li>Erythromycin.</li><li>Oestrogens.</li><li>Corticosteroids (For further information see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-inhaled/\">Corticosteroids - inhaled</a>, <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/\">Corticosteroids - oral</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a>).</li><li>Chlorpromazine.</li><li>Halothane toxicity.</li></ul></li><li><strong>Metabolic:</strong><ul><li>Ischaemic hepatitis.</li><li>Wilson's disease.</li><li>Haemochromatosis.</li><li>Alpha-1-antitrypsin deficiency.</li></ul></li><li><strong>Autoimmune:</strong><ul><li>Primary biliary cirrhosis.</li><li>Primary sclerosing cholangitis.</li><li>Autoimmune hepatitis.</li></ul></li><li><strong>Malignancy and infiltrative:</strong><ul><li>Cholangiocarcinoma.</li><li>Extrinsic compression from other malignancy.</li></ul><ul><li><a class=\"topic-reference external-reference\" href=\"/topics/tuberculosis/\">Tuberculosis</a>.</li><li>Lymphoma.</li><li>Amyloidosis.</li><li>Sarcoidosis.</li><li>Non-metastatic renal carcinoma.</li><li>Metastatic carcinoma.</li></ul></li></ul></li></ul><!-- end field cd4001ae-db0c-4b38-990c-9ebdcfa80f3a --><!-- end item 519a0e4e-3fd2-4e9a-9604-238cd10ad230 -->","topic":{"id":"9bb2b66b-9dcb-5ca7-ac32-56b20abf186b","topicId":"377bda8d-d3d4-4db0-9e52-f37661e8dd80","topicName":"Gilbert's syndrome","slug":"gilberts-syndrome","lastRevised":"Last revised in October 2015","chapters":[{"id":"61548d32-4743-5f65-9106-1d1b2c8a5b41","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8713d500-1912-5e94-9e2a-41cc82c4f2ec","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6ad04134-a509-5de0-893f-ae8194a670e7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"e49b7532-5573-5509-8cc6-aaac9da62112","slug":"changes","fullItemName":"Changes"},{"id":"988f1432-4338-5cac-ab53-356beb3f6ffa","slug":"update","fullItemName":"Update"}]},{"id":"11acffce-feeb-5a59-a9ee-5e20368b33be","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"72e476f3-3c50-591b-8b11-a18202a33e02","slug":"goals","fullItemName":"Goals"},{"id":"e206d7f3-d3f0-5956-b981-500f313f92e2","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"81c9afa4-2c89-5fdf-9c64-d31f2ecd1f4c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"eeb0d33d-78c1-53ca-afd5-2904551c6a18","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a21c1e57-9202-5a0a-be2e-5a142c8f900d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b6782d93-55a7-580e-98a6-d64c4e3294ce","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c8c17e29-b8d0-5c7f-a4a9-7dde6177bc7e","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e24fe645-a85b-5a66-9068-d7a899d67e03","slug":"definition","fullItemName":"Definition"},{"id":"2a19889d-d488-5a9c-9a39-d6facdb0fef7","slug":"prevalence","fullItemName":"Prevalence"},{"id":"903d69e0-4c2f-54bb-9201-41b4abe3c4b2","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"c208b531-d221-5241-9a72-2fba467a5681","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c123dacb-e2d1-5f4d-b5dc-22b8019a6765","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"578cdf4b-918a-512a-a4da-17daec1cb96c","slug":"assessment","fullItemName":"Assessment"},{"id":"56e4f62e-6140-5b88-b779-3cf820e68d7e","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1f5c4b39-f0cc-5c69-a702-4d06aba01390","fullItemName":"Management","slug":"management","subChapters":[{"id":"595bcb48-3809-5c4e-a821-6698776addc3","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"32266a41-fc2e-5310-9f85-e2a0b4e5be21","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6919b555-53e4-50c5-ba23-c440e8111dc4","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4d62a2f9-615d-5793-b494-d30df86ac7d3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"2f1d1ec8-610e-552c-b67c-ca7a4fda7d58","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3ba2b9a7-2c0f-5e0c-9c4d-8e6eeae3e515","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4293e047-b11c-5a5a-a9f1-30b755833eb0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"67c0566b-541b-5abd-93ac-0071e10f84c5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"395fc5e7-89b7-55fd-be1a-45c8cb627a14","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c208b531-d221-5241-9a72-2fba467a5681","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"9215b6a8-e298-5686-a7f2-ed76d76984ce","slug":"basis-for-recommendation-4b2","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 0c84d1a4-2d50-42ae-9179-5b4a6ae813cc --><h3>Basis for recommendation</h3><!-- end field 0c84d1a4-2d50-42ae-9179-5b4a6ae813cc -->","summary":null,"htmlStringContent":"<!-- begin item 4b2188ee-b611-4ecc-b2f2-eaff27785b7a --><!-- begin field ca6161de-e297-43a7-b510-75807b3a79f8 --><p>The information on the differential diagnosis of unconjugated and conjugated hyperbilirubinemia is based on expert opinion in the Oxford textbook of medicine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gilberts-syndrome/references/\">Thompson, 2010</a>], expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gilberts-syndrome/references/\">Esteban and Perez-Mateo, 1999</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gilberts-syndrome/references/\">Hirschfield and Alexander, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gilberts-syndrome/references/\">Claridge, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gilberts-syndrome/references/\">Sticova and Jirsa, 2013</a>] and the expert opinion of a previous external reviewer of this CKS topic.</p><!-- end field ca6161de-e297-43a7-b510-75807b3a79f8 --><!-- end item 4b2188ee-b611-4ecc-b2f2-eaff27785b7a -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}